Treatments for alopecia areata (AA) have evolved over the decades from broad and nonspecific therapies to those that are now more targeted and rationally selected. This was achieved by means of close cooperation and communication between clinicians and basic scientists, which resulted in the elucidation and understanding of the unique pathophysiology of AA. In this review we discuss this evolution and how novel therapies for AA have changed over the decades, what we have in our current arsenal of drugs for this potentially devastating disease, and what the future holds. (J Allergy Clin Immunol 2018;141:499-504.) 
Before alopecia areata (AA) was classified accurately as an autoimmune disease in the 1960s by Rothman, after detailed descriptions of its immune infiltrate, 1 it was associated with parasitic or syphilitic infections, ''neurotic'' tendencies, and endocrine dysfunction. As our understanding of the immune system improved in the 20th century, the classic immune infiltrate at the hair bulb in patients with AA was identified as the main culprit of hair loss.
AA is now established as a relatively common autoimmune disease of the hair follicle, affecting approximately 2% the population, with a spectrum of severity that ranges from patches on the scalp to hair loss over the entire body, also known as alopecia universalis (AU). Most treatments used for AA are general suppressors of the immune system or have been borrowed from other diseases. Until recently, the detailed pathophysiology of AA has been unknown, resulting in a ''best-guess'' approach when adopting novel therapies for desperate patients. These historical treatments will be reviewed, followed by discussion of a new era of targeted and rational therapies that arose from hypotheses driven by preclinical research (Fig 1) .
ESTABLISHED THERAPIES: NONSPECIFIC IMMUNOSUPPRESSION
Corticosteroids have been the mainstay of treatment for the majority of patients with AA for several decades. Topical or intralesional corticosteroids are usually the first-line therapy for limited or patchy disease, and pulse systemic methylprednisolone has been used for extensive disease, with varying success. The depth of the immune infiltrate in scalp skin (at the level of the hair bulb) makes topical corticosteroids a poor choice for most forms of AA, but they are often used in pediatric cases in which intralesional delivery might be poorly tolerated. However, in randomized controlled trials of topical corticosteroids, the beneficial effects are usually modest 2, 3 and in some cases are not statistically significant when compared with placebo. 4 Clinical response (defined as > _50% improvement in the Severity of Alopecia Tool score) with intralesional triamcinolone is usually in the range of 50% to 80% and has been reported to reach as high as 97%. 5, 6 Intralesional triamcinolone is usually tried for 6 months before moving the patient on to second-line therapies. Side effects of topical corticosteroids can include folliculitis, and intralesional corticosteroids can be associated with dermal atrophy or telangiectasia.
Systemic immunosuppression is usually reserved for extensive disease. Oral corticosteroids, methotrexate, and cyclosporine have been used to treat AA, with efficacies that range from 25% to 75%. [7] [8] [9] However, their significant adverse effects and requirement for stringent patient monitoring precludes them from being widely used in the treatment of AA.
CONTACT IMMUNOTHERAPY
By the 1960s, the concept that AA can be immune mediated was still novel, and the logical approach at the time was to perturb the pathogenic immune response by any means possible. This led to initial attempts to treat AA by inducing a local skin reaction with compounds like dinitrochlorobenzene, chrysarobin, liquid nitrogen, high-pressure mercury-arc radiotherapy, and psoralen UVA radiation. These attempts evolved into use of dithranol/anthralin (a potent psoriacide at the time) at low concentrations of 0.2% to 0.8%, which produced irritant dermatitis with occasional regional lymphadenopathy but no serious side effects. 10 This was found to be effective in the treatment of AA, but the dose had to be high enough to produce dermatitis. 11 Currently, contact immunotherapy for AA is practiced in many tertiary centers by using topical diphenylcyclopropenone or squaric acid dibutylester in a controlled clinical environment to induce the required dermatitis. Topical diphenylcyclopropenone/ squaric acid dibutylester was also effective in treating C3H/H3J mice, which spontaneously have an autoimmune form of hair loss that closely mimics human AA. 12 The mechanism of action of contact immunotherapy was proposed to be a normalization of the dermal CD4/CD8 ratio, as well as a restoration of hair follicle immune privilege, by reducing the expression of MHC class I and II molecules in the hair follicle. 12 In patients with AA, although contact immunotherapy requires commitment to a rigorous treatment schedule and carries the risk of allergic reactions in the form of lymphadenopathy or contact urticaria/angioedema, it has proved to be a viable and affordable option.
PHOTOTHERAPY
The popularity of phototherapy in the treatment of dermatological conditions led to development of the 308-nm excimer laser, which emits monochromatic UVB rays. Its use is widespread in the treatment of psoriasis, vitiligo, and atopic dermatitis and even various forms of cutaneous lymphoma. The mechanism of action is thought to be depletion of cutaneous T cells through induction of apoptosis. 13 The 308-nm excimer laser is effective in patients with AA with minimal side effects, 14, 15 making it ideal for pediatric patients whose caretakers might be reluctant to use steroids or contact immunotherapy treatments.
MICRONUTRIENT SUPPLEMENTATION
Dietary causes are frequently examined in patients with many diseases, and iron deficiency should be excluded in any patient presenting with diffuse alopecia. Although AA itself is not associated with iron deficiency, 16 it has been linked to vitamin D deficiency 17 and low levels of other trace elements, such as zinc and selenium. 18, 19 Presently, there has been no established mechanistic link between AA and these elements, and many clinicians are still asked constantly by patients whether changes in diet or supplementation can help in AA treatment.
Unfortunately, the evidence for these beneficial effects is lacking, 20 and dietary advice should remain general and enforce moderation rather than oversupplementation.
DRUGS FOR PSORIASIS: TNF ANTAGONISTS AND PHOSPHODIESTERASE 4 INHIBITOR
At the turn of the 21st century, dermatologists became enthusiastic about first-generation TNF antagonists after these drugs were shown to have excellent results in the treatment of psoriasis. Thus, despite initial observations that AA can actually be precipitated by TNF inhibition, [21] [22] [23] biological therapies, such as efalizumab, etanercept, and alefacept, were attempted in randomized, placebo-controlled trials for AA, with disappointing results. [24] [25] [26] Learning from the past, much more scrutiny is applied now to potential ''borrowed'' drug candidates. Phosphodiesterase 4 inhibitors have been developed as small-molecule innate immune system modulators that downregulate IFN-g production by reducing cellular cyclic AMP levels. For example, apremilast (Otezla; Celgene, Summit, NJ) has been approved for use in psoriasis and psoriatic arthritis by the US Food and Drug Administration (FDA). 27 Apremilast has been shown in preclinical studies to be effective in preventing hair loss in a humanized AA-like graft on a mouse, 28 providing a rationale for pilot testing in human patients with AA.
DRUGS FOR CARDIOVASCULAR DISEASE: SIMVASTATIN/EZETIMIBE
After a case report of a human patient with long-standing, treatment-resistant AU experiencing patchy hair regrowth after being treated with combination simvastatin and ezetimibe for hyperlipidemia, 29, 30 clinicians began to test this novel therapy for patients with recalcitrant AA. Simvastatin/ezetimibe therapy has been associated with reductions in oxidized lipoproteins when compared with statin monotherapy. 31 This is believed to contribute to its superiority in suppressing atherosclerosis, which can have a significant T H 17 component. Initial reports on the efficacy of this treatment in patients with AA were negative 32 ; however, the results of a more robust and controlled clinical trial are awaited (Clinical Trial no. NCT01520077).
DRUGS FOR GLAUCOMA: PROSTAGLANDIN ANALOGS
When patients receiving topical bimatoprost for open-angle glaucoma and ocular hypertension unexpectedly reported longer and thicker lashes as a side effect, 33 the hair research community quickly focused their efforts on uncovering a role for prostaglandin F2a in accelerating anagen hair growth and stimulating follicular melanocyte stem cells. 34 Latisse (bimatoprost 0.03% solution; Allergan, Dublin, Ireland), was approved by the FDA for the treatment of ''eyelash hypotrichosis'' in December 2008, in part because of its long safety record in the ophthalmological field. Bimatoprost was then adopted for use in stimulating regrowth in patients with AA with eyelash involvement, 35, 36 with mixed results likely influenced by the activity of the immune system at the time of treatment. Although prostaglandin analogs have also been used to treat scalp AA with modest success, 37, 38 their high cost and variable results relegate it to a third-or fourth-line option.
DRUGS AND TREATMENTS FOR ANDROGENETIC ALOPECIA: MINOXIDIL, LOW-LEVEL LIGHT THERAPY, AND HAIR TRANSPLANTATION
Treatments for androgenetic alopecia (AGA) have also been tested in patients with AA with varying rates of success. Topical Minoxidil, which is FDA-approved for AGA after being developed as a drug for hypertension, is frequently used in cases of AA or in combination with other modalities (corticosteroids and contact immunotherapy) in patients with limited AA, in whom it might play a role in preventing posttreatment shedding. 39 Low-level light therapy has been a somewhat controversial novel treatment for AGA, which comes in the form of a handheld device that emits red light (wavelength of around 655 nm) onto the scalp. It is postulated to work through a process known as ''photobiomodulation,'' whereby signaling pathways in the cytosol and mitochondria are activated by engagement of cytochrome chromophores by red and infrared wavelengths. 40 Although it has yet to be evaluated in patients with AA, low-level light therapy has been shown to be effective in the early limited phase C3H/HeJ mouse model of AA 41 but not in patients with more extensive disease. 42 Hair transplantation is not recommended in patients with AA. The potential for autoimmune attack and destruction of the grafted follicles is a highly likely outcome, which would preclude patients with AA from this option of treatment. The prospect of bioengineered hair follicles from induced pluripotent stem cells 43 genetically edited to be devoid of MHC and immunomodulatory molecules might avoid this problem entirely 44 and bring hope to future patients with severe AA/AU.
NOVEL THERAPIES: RATIONAL APPROACHES
The past decade has supplied us with precision molecular and genetic tools that allow us to investigate the intricate web of interactions that comprise the pathophysiology of complex diseases. Genome-wide association studies (GWASs) have uncovered susceptibility loci that contribute to an increased risk of AA, whereas gene expression analyses, such as RNA sequencing or microarray studies, have illuminated the pathogenic processes that occur in the skin. These highdimensional data sets can be analyzed computationally to give rise to network ''nodes'' or master regulators, which are defined as genes or transcription factors that govern large swaths of the observed phenotype. These large data sets provide a comprehensive and rational list of druggable targets that can be probed further and fed into a drug development or repurposing pipeline.
Abatacept
Abatacept is a soluble form of cytotoxic T lymphocyteassociated antigen 4 (CTLA-4; CTLA-4-Ig), which is a costimulatory ligand involved in T-cell activation in response to antigen. CTLA-4 levels were found to be increased on T cells from patients with AA as a possible survival factor, 45 and it was identified as a replicated susceptibility locus in several genetic studies. 46, 47 Abatacept was developed for use in patients with rheumatoid arthritis (RA) and is being tested in patients with a wide range of autoimmune diseases. An open-label, pilot clinical trial is currently underway to assess its role in patients with moderate-to-severe patchy AA (Clinical Trials no. NCT02018042).
T H 2 and T H 17 antagonists
Anecdotal evidence has frequently associated AA with atopic comorbidities, 48 and this has been confirmed in small-scale population-based studies. 49 However, most of the preclinical work has pointed to a T H 1 skewing of the immune system in patients with AA, 50 with significant roles attributed to key T H 1 players, such as interferon and CD8 1 T cells. Recently, more detailed analysis of the immune milieu of active AA lesions has uncovered a remarkable heterogeneity in the immune system, including a prominent T H 1 signature, as well as a more limited evidence for T H 2 activation and IL-23 signaling. 51 This result has prompted the hypothesis that AA might be a heterogeneous entity, and patients can have varied immune profiles according to the genes, sex, and stage of disease. Ustekinumab, an mAb targeting the IL-12/IL-23 p40 subunit, was reported to be somewhat effective in 3 cases of extensive AA, 52 and placebo-controlled studies are awaited to assess the true efficacy of these therapies for patients with AA.
Janus kinase inhibitors
Janus kinase (JAK) inhibitors have provided the clearest and most successful example of the treatment development process in patients with AA. The initial GWAS for patients with AA carried out in about 1000 patients with AA from the National AA Registry uncovered genes involved in antigen presentation (HLA) and immunomodulation (CTLA4 and IL2RA). 46 Interestingly, genes encoding the cellular ''danger signals'' ULBP3/ULBP6 were also identified as the most significant association after the HLA locus, and expression of these and other danger signals was confirmed to be upregulated on the hair follicles of patients with AA, [53] [54] [55] as well as the C3H/HeJ murine AA model. 54 A second GWAS carried out on a different continent also confirmed the significance of this locus. 56 Further analysis J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 2 identified the immune cell type that recognizes these danger signals to be a subset of cytotoxic CD8 1 effector T cells expressing the NKG2D surface marker, which depends on the survival cytokine IL-15 and shares signaling pathways with the T-cell survival factors IL-2 and IL-7 (Fig 2) . Data from the GWAS showed that AA shared susceptibility genes with other autoimmune conditions, such as type 1 diabetes, RA, and celiac disease, 57 and the CD8 1 NKG2D 1 subset of T cells was a common pathogenic cell type in these diseases.
JAK inhibitors were repurposed from other diseases to target CD8 1 NKG2D 1 T cells, with the rationale that this would interfere with the survival signals from essential cytokines, such as IL-2 and IL-15, as well as the cytotoxic cytokine IFN-g (Fig 2) . Both tofacitinib (a pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor), which are FDA approved for RA and myelodysplasia, respectively, were effective in preventing and reversing AA in the C3H/HeJ murine model of AA by targeting this specific subset of killer T cells. 54 Subsequently, many case reports provided strong anecdotal evidence that these drugs and baricitinib, another JAK1/2 inhibitor, might be effective in the treatment of AA (Table  I) . 54, [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] Subsequent clinical trials showed that oral JAK inhibitors were also extremely effective in patients with extensive disease with minimal side effects. 58, 76 However, relapses are common after cessation of therapy, inviting future randomized placebo-controlled trials to establish long-term efficacy and safety and optimize dosing regimens.
Topical JAK inhibitors are currently in development, with several at various stages of drug development. 77 Theoretically, topical application of JAK inhibitors will ensure higher local concentrations at the end-organ, reduce systemic absorption and potential side effects, and potentially have a beneficial effect on hair follicle stem cells in terms of stimulating regrowth. 78 Furthermore, specific JAK inhibitors (JAK1 vs JAK2 vs JAK3) are currently under investigation for their efficacy in the treatment of AA and other autoimmune disorders. 79, 80 Despite its rational development, the response rate (> _50% improvement in the Severity of Alopecia Tool score) across the initial open-label studies with JAK inhibitors is only around 70%. [58] [59] [60] [61] [62] Other case reports have also described cases of treatment failure in patients with AU. 72 This suggests that there might be significant disease heterogeneity in patients presenting with AA, either at the level of disease pathophysiology or at the stage of their disease. Scoring systems that incorporate disease severity and biomarkers are currently being developed to predict which patients might benefit from JAK inhibition and which might be nonresponders. For example, the Alopecia Areata Disease Severity Index incorporates selected gene expression data from microarray analysis of AA lesional skin in patients. 76, 81 Selected genes, such as those corresponding to keratin production, interferon signaling, and cytotoxic T-cell recruitment, are considered and provide a surrogate for the patient's stage and severity of disease. Initial analyses have shown that the Alopecia Areata Disease Severity Index correlates well with the patient's stage and presentation of disease and with the response to JAK inhibition. Testing this index in larger cohorts of patients will establish its predictive value in the future management of AA.
CONCLUSION
The history and trajectory of novel therapies in patients with AA exemplifies the advances made in the scientific community. As our clinical knowledge improves, technological and bioinformatic advances contribute to moving us from ''best-guess'' remedies to targeted, rationally designed selected treatments by understanding the unique pathophysiology of AA. Given the history perspective of disparate AA treatments, we should consider the existence of subsets or different stages of AA that might respond to different treatment strategies. Early studies that identify biomarkers for AA 81 and deep sequencing and cataloguing of genetic variants 82 will inform these future approaches.
Our current approach, using drugs that specifically target a subset of immune cells, will be further refined by personalized treatments that are tailored to the individual patient. Our current understanding of the immune cell subsets involved in AA pathogenesis is limited to effector T cells, and the involvement of other cell types, such as regulatory T cells and macrophages, is still unknown. Future works in uncovering network and microenvironmental interactions in patients with AA and how they are affected by treatment, particularly with JAK inhibitors, will be invaluable in enhancing our understanding of AA and likely other autoimmune diseases.
